Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/18/2008
 
First Published:
9/1/2000
1.
Phase III Randomized Study of Adjuvant Pegylated Interferon alfa in Patients With Previously Resected Stage III Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 70
Other
EORTC-18991
NCT00006249
Last Modified:
7/1/2000
 
First Published:
10/1/1998
2.
Phase I/II Study of Pegylated-Interferon Alfa-2a in Previously Untreated Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (Summary Last Modified 07/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
MSKCC-98052
ROCHE-NO15753C, UCLA-9903045, NCI-G98-1475, NCT00003542
Last Modified:
5/1/2002
 
First Published:
7/1/2000
3.
Phase II Study of Pegylated Interferon alfa-2b in Patients With Minimally Treated or Previously Untreated Advanced Low-Grade Non-Hodgkin's Lymphoma (Summary Last Modified 05/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
MSKCC-99101
NCI-G00-1814, NCT00006039
Last Modified:
7/26/2005
 
First Published:
12/1/2001
4.
Phase II Study of Temozolomide and Pegylated Interferon alfa in Patients With Advanced Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
MSKCC-01005
NCI-G01-2031, NCT00027742
Last Modified:
9/11/2008
 
First Published:
5/29/2008
5.
Study of the Effects of Immune-Modulating Therapies on Tissue Expression of Indoleamine 2, 3 dioxygenase in Patients With Untreated Acute or Chronic Hepatitis C, Metastatic Melanoma, or Crohn Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Biomarker/Laboratory analysis
Completed
No age specified
NCI
VU-VICC-MEL-0651
VICC-MEL-0651, VU-VICC-060614
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute